Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

NEXT STORY
Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
PREV STORY
Stedical Scientific Announces Completion of Acquisition of PermeaDerm, Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

PositiveID Announces Medical Device Subsidiary 2018 Trade Show Schedule

DELRAY BEACH, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Diversified life sciences company, PositiveID ...

author_avatar
NASDAQ Market News

ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

The funding will be used for the clinical development of QR-313 Clinical trial in ...

author_avatar
NASDAQ Market News

Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study

Top line results showed larazotide having a significant effect on intestinal permeability, a mechanism ...

author_avatar
NASDAQ Market News